Navigation Links
Pathfinder Initiates Minimally Invasive Surgical Navigation Study
Date:11/15/2010

NASHVILLE, Tenn., Nov. 15, 2010 /PRNewswire/ -- Pathfinder Therapeutics, Inc. has initiated a clinical study to assess the value of Explorer™, its image-guided surgical platform, in minimally invasive liver resections and ablations.  Clinical sites participating in the study include: Memorial Sloan-Kettering Cancer Center, University of Pittsburgh Medical Center, Providence Portland Medical Center, and UNC-Chapel Hill.

Minimally invasive procedures are performed through a few small incisions rather than one large incision.  As a result, these techniques can significantly reduce postoperative pain and patient recovery time compared with traditional surgery.

"We are excited to partner with these highly-regarded institutions to build upon the success of previous clinical studies showing that Explorer™ can provide accurate instrument tracking and guidance during open liver procedures. Despite its known benefits, minimally invasive liver surgery has not attained widespread use, in part due to the advanced skills and technological experience required to perform such procedures safely.  Explorer™ combines state-of-the-art surgical navigation and 3D visualization of preoperative imaging, thereby facilitating the transition from standard techniques to novel laparoscopic techniques for surgeons with less experience and formal training while also providing assistance to highly experienced surgeons," said Skip Goode, CEO of Pathfinder.

As part of the study, preoperative CT or MR imaging is registered to the intraoperative position of the liver, providing surgeons with enhanced visualization of the liver anatomy as well as real-time positioning of surgical instruments, including resection and ablation devices.  Rather than guess where underlying vessels and tumors are, surgeons can be confident they are precisely targeting the anatomical structures they have planned on, thus minimizing costly mistakes which can increase the risk of postoperative complications.  This ability to "see through the liver" in 3D is especially helpful during minimally invasive procedures, where the surgeon is unable to physically manipulate the liver as is possible during traditional surgery.

About Pathfinder Therapeutics, Inc.

Pathfinder Therapeutics, Inc. is a medical device company dedicated to increasing the number and effectiveness of surgeries on abdominal and other soft tissue organs.  Pathfinder is the first company to receive FDA clearance for a medical device to navigate liver surgery using preoperative medical images. The Explorer™ navigation system uses state-of-the-art optical tracking and surface registration techniques to show surgeons where they are in the context of their target organ and underlying structures.  For more information, go to www.pathsurg.com.


'/>"/>
SOURCE Pathfinder Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
2. American Regent Initiates Voluntary Recall of Magnesium Sulfate Injection, USP 50% (25 grams/50 mL), 50mL Single Dose Vial Lot # 0491
3. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
4. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
5. Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinsons Disease
6. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
7. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
8. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
9. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
10. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
11. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):